SeekingAlpha · Aug 21, 2026
RA
NASDAQ · RAPP
Rapport Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$50.83
Down-$1.67 (-3.18%)
Updated Aug 28, 2026, 1:06 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.05B
- P/E ratio
- -111.89
- Dividend yield
- 0.00%
- 52-week range
- $26.01 – $52.83
- Volume
- 382.83K
- Avg. volume
- 522.83K
Price performance
RAPP price history
1M range · 0 trading sessions · Daily adjusted prices
RAPP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest RAPP news
The latest Smart Investors Daily articles mentioning RAPP.
Stock researchCompany · Overview
RAPP research
Overview
Company profile and research snapshot.
Company profile
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BTIG | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| Jul 16, 2026 | BTIG | Buy | — |
| Jun 24, 2026 | Leerink Partners | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 19, 2026
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
Benzinga · Aug 12, 2026
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
Benzinga · Aug 5, 2026
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
